Having trouble accessing articles? Reset your cache.

Tyra raises $50M series A for cancer drug resistance

Tyra Biosciences emerged from stealth with a $50 million series A round to bring its first therapy to the clinic for drug-resistant cancer.

Alta Partners, RA Capital Management, Boxer Capital of

Read the full 306 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE